Article Text
Statistics from Altmetric.com
Editor,—McKenzie and Apostolopoulos' recent article on immunotherapy for pancreatic carcinoma (Gut1999;44:767–769) gave an excellent overview. We agree that the poor prognosis of this disease makes it imperative that new agents and novel therapeutic strategies are investigated. However, although this paper discusses classical immunotherapy (where immune competent cells are stimulated to attack pancreatic cancer cells directly), the induction of antibodies directed against growth factors by immunisation (where the immunogen stimulates the immune system to inhibit the growth of tumour cells indirectly) is not mentioned. We are currently undertaking a phase II clinical trial for inoperable pancreatic cancer using one such immunogen, Gastrimmune, which induces neutralising antibodies against amidated gastrin-17 and its precursor glycine extended gastrin-17 (this immunogen is also undergoing a phase II trial for gastric cancer at the University Department of Surgery, Nottingham, UK).
Gastrin has been shown to be a growth factor in a variety of malignancies including colorectal, gastric, and pancreatic cancers in both in vitro and in vivo studies1; precursor forms such as progastrin and glycine extended gastrin also have a trophic effect.2 More recently the autocrine/paracrine pathway, in which tumour cells produce and respond to gastrin, has been shown to be increasingly important.3 In vitro and in vivo studies have also shown the trophic effect of gastrin and the inhibitory effect of both gastrin receptor antagonists and anti-gastrin antibodies,1 4 5 and further studies …
Professor McKenzie